People · Operator
Named in public records as an officer, director or promoter · active 2008–2024 · Pharma, Biotechnology, AI / ML, Other Health Care, Pharmaceuticals, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Bright Peak Therapeutics, Inc. | — | Pharma | Series D+ | $196.5M | $1.0B | 2024 |
| E-scape Bio, Inc. | — | Biotechnology | Series C | $167.1M | $2.8B | 2015 |
| Genocea Biosciences, Inc. | — | Biotechnology | Series C | $153.6M | $3.0B | 2012 |
| PAIGE.AI, Inc. | — | AI / ML | Series C | $145.5M | $316.1M | 2021 |
| ImmPACT Bio USA Inc. | — | Biotechnology | Series D+ | $143.6M | $3.5B | 2020 |
| Adicet Bio, Inc. | — | Biotechnology | Series C | $116.8M | $3.3B | 2019 |
| Celladon Corp | — | Biotechnology | Series B | $70.9M | $119.1M | 2008 |
| Catalyst Biosciences Inc | — | Biotechnology | Series C | $65.3M | $77.4M | 2008 |
| Petra Pharma Corp | — | Biotechnology | Series B | $58.8M | $1.1B | 2015 |
| Iscience Interventional Corp | — | Other Health Care | Series B | $40.3M | $61.1M | 2011 |
| Aquinox Pharmaceuticals (Usa) Inc | — | Pharmaceuticals | Series A | $30.6M | $433.6M | 2013 |
| SonoThera, Inc. | — | Biotechnology | Series B | $30.4M | $550.2M | 2022 |
| Magnolia Neurosciences Corp | — | Biotechnology | Series B | $26.4M | $724.5M | 2018 |
| Aldeyra Therapeutics, Inc. | — | Biotechnology | Series A | $24.6M | $361.5M | 2012 |
| Lodo Therapeutics Corp | — | Biotechnology | Series B | $19.9M | $788.5M | 2015 |
| Rodeo Therapeutics Corp | — | Biotechnology | Series A | $14.3M | $323.6M | 2017 |
| Proniras Corp | — | Other | Series A | $11.2M | $37.2M | 2017 |
| ApoGen Biotechnologies, Inc. | — | Biotechnology | Series A | $7.6M | $273.5M | 2016 |
Asish Xavier at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Asish Xavier on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.